The future of heart disease treatment is bold

Tenaya is using biological insights from our team and our collaborators to discover novel therapies for various forms of heart disease, the leading cause of mortality worldwide. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease. As displayed below, each of our product platforms is designed to address different problems that have historically plagued the development of novel therapies for heart disease.

Cellular Regeneration

Our Cellular Regeneration platform uses viral vectors to deliver genes to specific cells in the heart to regenerate cardiomyocytes in vivo. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the loss of cardiomyocytes. We believe this platform has the potential for broad utility across a range of heart conditions that result in the loss of cardiomyocytes, including myocardial infarction, chemotherapy-related toxicity, and viral infection.

Gene Therapy

Our Gene Therapy platform uses AAVs to deliver genes to specific cells in the heart to correct or compensate for functional defects. We have the ability to use both known AAV capsids as well as novel capsids identified through our internal capsid engineering capabilities to target cardiomyocytes, cardiac fibroblasts  or other cells important to the proper functioning of the heart. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the underlying problems that contribute to heart disease. We believe this platform has potentially broad utility for both genetic and non-genetic forms of heart disease.

Precision Medicine

Our Precision Medicine platform uses human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as proprietary disease models and analysis of human genetics for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on efficacy in animal models to develop therapies intended for human heart disease. We believe this platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner—including gene therapy, small molecules, and biologics—for both genetic and non-genetic forms of heart disease.

Drug Development Capabilities

We have internalized and integrated core capabilities to support our product platforms and our pipeline programs. We believe these capabilities can collectively support more rapid product development, precise delivery of our therapies to the heart, and more efficient and scalable manufacturing of our products. Taken together, these capabilities may ultimately improve the probability of technical and regulatory success of our product candidates that we hope to bring to patients who are fighting different forms of heart disease.

Disease Models

We have internalized the ability to create and integrate proprietary in vitro and in vivo models within our research organization. For our in vitro hiPSC-CM disease models, we use multiple methods to induce phenotypes within cell lines that simulate human diseases and then use these models for high throughput target identification and drug discovery. For our in vivo disease models, we have a dedicated onsite in vivo pharmacology group and vivarium, where we have established approximately 15 rodent heart disease models, both genetic and non-genetic, and can dose animals, perform heart surgeries, and use non-invasive imaging to assess the impact of our therapies under development.

Capsid Engineering

We have established in-house AAV capsid engineering capabilities and have successfully screened over one billion variants from more than 30 diverse, proprietary AAV libraries in multiple in vitro, in vivo, and in silico models to discover novel AAV capsids that can target the different types of cells in the heart. These capsids are designed to have desirable properties including the ability to more selectively target the heart versus other organs as well as lower susceptibility to neutralizing antibodies. We believe our capsid engineering efforts will be critical in supporting the successful clinical development of our product candidates and enabling those product candidates, if approved, to reach more patients.

Promoters and Regulatory Elements

We have created novel promoters and regulatory elements to support our gene therapy and cellular regeneration programs. We use these innovations to help ensure more precise and more robust expression of therapeutic payloads in the different cell types of the heart as compared to what can be achieved with currently available methods. We believe our innovations can support successful clinical development in part by improving the efficacy and safety profile of our product candidates.

Drug Delivery

We are actively exploring different routes of administration (ROAs) as well as different infusion- and injection-based methods for delivering our AAV-based therapies. We have designed a new catheter to support more targeted delivery and more efficient uptake of therapeutic payloads in the heart.

Manufacturing

We have taken important steps towards internalizing both current Good Manufacturing Practice (cGMP) and non-GMP AAV manufacturing capabilities to support our emerging portfolio of gene therapy and cellular regeneration product candidates. This includes a growing in-house team of approximately 25 personnel that can support process development (PD), analytical development (AD), and quality assurance (QA) and quality control (QC). We have produced non-clinical material involving both parental and novel AAV capsids at the 50L and 200L scales to support early research and IND-enabling studies in small and large animal models. We have initiated construction of a cGMP facility in the San Francisco Bay Area, near our research labs, to enable smooth scale-up of production to support first-in-human (FIH) studies, initially at the 1000L scale. We expect this facility will be operational in the first half of 2022.

Collaborations

Tenaya’s mission is to discover, develop, and deliver therapies that address the underlying drivers of heart disease. We were founded by leading cardiovascular scientists from, and have established academic collaborations with, Gladstone Institutes and University of Texas Southwestern Medical Center, and have forged additional partnerships aimed at helping advance our groundbreaking therapies. We are always open to strategic collaborations to push new boundaries in the treatment of heart disease.

For partnering inquiries, please contact us at partnering@tenayathera.com.

Publications & Presentations

MYBPC3 Gene Therapy Program

2021 American Society of Gene & Cell Therapy 24th Annual Meeting  |  Apr 27, 2021

Reversal of Cardiac Hypertrophy with an Optimized MYBPC3 Gene Therapy

DWORF Gene Therapy Program

HDAC6 Inhibitor Small Molecule Program

2021 European Society of Cardiology - Heart Failure Congress  |  Jun 29, 2021

HDAC6 Inhibition Improves Diastolic Function in a Mouse Model of Heart Failure with Preserved Ejection Fraction

2021 European Society of Cardiology - Heart Failure Congress  |  Jun 29, 2021

Phenotypic Screening Identifies HDAC6 Inhibitors as Cardioprotective Agents

Reprogramming Program

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Cardiac Direct Reprogramming Gene Therapy for Ischemic Injury

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Efficacy of Cardiac Reprogramming via Gene Therapy in Rat with Chronic Heart Failure

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Developing an Optimized Cardiac Reprogramming Cocktail for Gene Therapy in Humans

Gene Therapy Capsid Engineering

2020 American Society of Gene & Cell Therapy 23rd Annual Meeting  |  May 12, 2020

Engineering Novel rAAV Vectors with Enhanced Cardiac Tropism

Looking to collaborate? Interested in new career opportunities at Tenaya?
Want to know more?

CONTACT US